Precigen (PGEN) to Release Quarterly Earnings on Wednesday

Precigen (NASDAQ:PGEN) is expected to be issuing its Q1 2026 results after the market closes on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.03) per share and revenue of $20.8070 million for the quarter. Individuals may review the information on the company’s upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:30 PM ET.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings results on Wednesday, March 25th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.09. The firm had revenue of $4.57 million during the quarter, compared to analysts’ expectations of $8.29 million. Precigen had a negative net margin of 2,588.21% and a positive return on equity of 2,317.96%. On average, analysts expect Precigen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Precigen Stock Down 0.2%

Shares of NASDAQ:PGEN opened at $4.20 on Tuesday. The stock has a market cap of $1.50 billion, a P/E ratio of -3.13 and a beta of 1.07. The firm has a fifty day moving average price of $3.79 and a 200 day moving average price of $4.07. The company has a debt-to-equity ratio of 4.46, a current ratio of 3.09 and a quick ratio of 2.83. Precigen has a 1-year low of $1.26 and a 1-year high of $5.47.

Insider Activity at Precigen

In other news, Director Randal J. Kirk sold 4,772,781 shares of the firm’s stock in a transaction on Monday, March 30th. The shares were sold at an average price of $3.30, for a total value of $15,750,177.30. Following the completion of the sale, the director owned 302,213 shares in the company, valued at approximately $997,302.90. This trade represents a 94.05% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 47.10% of the company’s stock.

Institutional Trading of Precigen

Several hedge funds have recently made changes to their positions in the company. Xponance LLC lifted its stake in shares of Precigen by 21.3% in the 4th quarter. Xponance LLC now owns 14,191 shares of the biotechnology company’s stock worth $59,000 after acquiring an additional 2,496 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Precigen by 6.1% in the 3rd quarter. BNP Paribas Financial Markets now owns 51,796 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 2,993 shares during the period. Intech Investment Management LLC lifted its stake in shares of Precigen by 5.2% in the 4th quarter. Intech Investment Management LLC now owns 63,018 shares of the biotechnology company’s stock worth $263,000 after acquiring an additional 3,137 shares during the period. HighTower Advisors LLC lifted its stake in shares of Precigen by 4.2% in the 4th quarter. HighTower Advisors LLC now owns 104,560 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 4,249 shares during the period. Finally, The Manufacturers Life Insurance Company lifted its stake in shares of Precigen by 10.3% in the 4th quarter. The Manufacturers Life Insurance Company now owns 56,006 shares of the biotechnology company’s stock worth $234,000 after acquiring an additional 5,222 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Citizens Jmp increased their price target on shares of Precigen from $8.00 to $9.00 and gave the stock a “market outperform” rating in a research note on Thursday, March 26th. Zacks Research upgraded shares of Precigen from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a research note on Tuesday, April 21st. HC Wainwright increased their price target on shares of Precigen from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, March 26th. Finally, Wall Street Zen upgraded shares of Precigen from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.50.

About Precigen

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.